Skip to main content

Gilead Sciences company profile

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and sells medicines, with a focus on virology, oncology and inflammation. Its commercial portfolio includes more than 25 therapies, among them HIV treatments and prevention products such as Biktarvy, Descovy, Genvoya and Yeztugo; hepatitis C and B treatments Epclusa and Vemlidy; cell therapies Yescarta and Tecartus; the breast cancer treatment Trodelvy; and AmBisome and Veklury. In the U.S., most products are sold through wholesale channels, with a large share of gross sales historically going to three wholesalers. Outside the U.S., products are marketed through commercial teams, third-party distributors and corporate partners. The company operates in more than 35 countries, with headquarters in Foster City, California, and manufacturing facilities in California, Ireland and Canada.

A summary of the business section of the company's latest annual report, filed 24 Feb 2026.

Company facts

TickerGILD · Nasdaq
SectorBiotechnology
IndustryBiotechnology
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK882095
Latest annual report10-K, filed 24 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Daniel P. O’DayChairman &amp; CEO · Director2.0M · < 1%Option exercise, 5 Nov 2026
Johanna MercierChief Comm &amp; Corp Aff Officer634K · < 1%Sale under a 10b5-1 plan, 15 Oct 2026
Andrew D. DickinsonChief Financial Officer376K · < 1%Sale under a 10b5-1 plan, 15 Oct 2026
Jacqueline K. Barton, Ph.D.Director122K · < 1%Grant or award, 30 Apr 2026
Kelly A. KramerDirector120K · < 1%Sale under a 10b5-1 plan, 28 Nov 2025
Harish ManwaniDirector103K · < 1%Grant or award, 30 Apr 2026
Sandra J. Horning, M.D.Director84.8K · < 1%Grant or award, 30 Apr 2026
Javier J. RodriguezDirector81.0K · < 1%Grant or award, 30 Apr 2026
Anthony WeltersDirector79.6K · < 1%Sale under a 10b5-1 plan, 26 Aug 2026
Deborah H. TelmanEVP, Corporate Affairs & GC59.4K · < 1%Option exercise, 12 Nov 2025
Jeffrey A. Bluestone, Ph.D.Director55.7K · < 1%Option exercise, 20 Aug 2026
Dietmar Berger, M.D., Ph.D.Chief Medical Officer29.5K · < 1%Shares withheld for tax, 10 Sep 2026
Ted W. Love, M.D.Director26.8K · < 1%Grant or award, 30 Apr 2026
Cain Wettan Keeley MEVP Gen Counsel, Legal &amp; Comp—Sale under a 10b5-1 plan, 6 Nov 2026
Burkhart ErinSVP, Controllership—Shares withheld for tax, 22 Sep 2026
Wilfong Diane E.Interim Corp Controller & CAO—Shares withheld for tax, 10 Sep 2025
Patterson SandraSVP, Controllership—Shares withheld for tax, 10 Mar 2025
Parsey MerdadChief Medical Officer—Shares withheld for tax, 10 Dec 2024

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

GILD in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.